STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 October 2004 please refer to module 8B**.**

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

Scope	Application number	Type of modification[1]	Notification/ Opinion issued on[2]	Commission Decision Issued/amended on
The MAH proposed to update the Summary of Product characteristics to reflect the safety information included in the 1st Periodic Safety Update Report, submitted in May 2001 and amended wording in relation to class labelling (St Johns wort interaction).	II/0001	II	18.10.01	26.03.02
Updated sections 4.8 and 5.1 of the Summary of Product Characteristics (SPC), following MAH submission for three 48 week study reports (M98-863, M98-957, M98-940), as part of the Specific Obligations agreed to by the applicant.	II/0002	II	18.10.01	26.03.02
The MAH applied to change the test procedure of the medicinal product.	I/0003	I	17.01.02	13.02.02
The MAH applied to change the specification of starting material/intermediate used in manuf. of the active substance	I/0004	I	27.02.02	06.03.02
The MAH applied to update the Summary of Product Characteristics (SPC) section 4.8 (Undesirable effects), to include hepatitis, and section 4.4 of the SPC (Special warnings and special precautions for use) to include a warning regarding patients co-infected with hepatitis.	II/0006	II	27.06.02	13.09.02
The MAH applied tochange the manufacturing process of the active substance	I/0007	I	16.08.02	18.09.02
The MAH applied for an extension of shelf life as foreseen at time of authorisation for the finished product.	I/0008	I	22.08.02	07.10.02
The MAH applied to change the test procedures of the medicinal product	I/0009	I	13.09.02	25.09.02
The MAH applied tochange the test procedures of the medicinal product	I/00010	I	13.09.02	25.09.02
The MAH applied to change the test procedures of the medicinal product	I/00011	I	13.09.02	25.09.02
The MAH applied to change the test procedures of the medicinal product	I/00012	I	13.09.02	25.09.02
Annual re-assessment of the specific obligtions and the benefit/risk profile of medicinal products authorised under exceptional circumstances	S/0005	S	27.06.02	-

[1] In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: **I** refers to a minor variation (Type I variation); **II** refers to a major variation (Type II variation); **I/II** refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; **X** refers to an Annex II application.
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

[2] For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.

Changes to the Patient Leaflet local representatives address and telephone number for Greece, contact company name for Iceland and minor corrections in compliance with the template.	N/00013	N	17.10.02	13.11.02
The MAH applied to update section 4.4 and section 4.8 of the Summary of Product Characteristics (SPC) further to the CPMP request to implement the class-labelling for "antiretroviral therapy (ART) and lipodystrophy". In addition, the MAH seeks to implement the CPMP recommendations on the latest PSUR with regard to hepatic side effects, affecting section 4.8 of the SPC and also seeks to streamline section 4.8 of the SPC in line with the CPMP Guideline on SPC.	II/14	II	19.03.03	09.07.03
The MAH applied tochange the specifications of active substance	I/15	I	11.06.03	26.06.03-
The MAH applied to update section 4.4 (Special warnings and special precautions) of the Summary of Product Characteristics (SPC) as a class labelling on liver impairment and anti-HIV products, and on further request also revised section 4.2 (Posology and method of administration) of the SPC and section 2 of the Package Leaflet (PL). Results of *in vitro* studies on prolongation of cardiac repolarisation are added to section 5.3 (Preclinical safety data) of the SPC.	II/16	II	20.11.03	30.01.04
The MAH applied to change the test procedure of active substance	I/17	I	05.08.03	18.08.03
The MAH applied to changethe name of a manufacturer of the medicinal product	I/18	I	07.10.03	
The MAH applied to update section 4.5 (Interaction with other medicinal products and other forms of interaction) of the Summary of Product Characteristics (SPC) following the assessment of four drug interaction studies aimed at evaluating the pharmacokinetics and safety of Kaletra co-administered with other approved protease inhibitors. In addition, following assessment of a study that evaluated the interaction between Kaletra and desipramine (a CYP2D6 marker substrate), the MAH seeks to amend section 4.3 (Contraindications), 4.4 (Special warnings and special precautions for use) and 4.5 (Interaction with other medicinal products and other forms of interaction) of the Summary of Product Characteristics (SPC), to remove the contraindication for co-administration with drugs dependent on the P450 isoenzyme CYP2D6 for their metabolism. A consequential change in section 2 of the Package Leaflet (PL) is also proposed.	II/19	II	20.11.03	30.01.04
The Mah applied to update sections 4.8 (Undesirable effects) and 5.1 (Pharmacodynamic properties) of the Summary of Product Characteristics (SPC) to reflect the long-term safety and efficacy data available from phase II study M97-720. The SPC, Package Leaflet (PL) and labelling have been updated to bring storage declarations in line with current guidelines and the list of local representatives in the new Accession Countries has also been added to the PL. Minor typographic errors in SPC are corrected and cross-references have been updated in line with QRD guidance	II/21	II	29.07.04	09.09.04
To update the wording in the hepatic statements within section 4.2 (Posology and method of administration), 4.4 (Special warnings and special precautions for use) and 5.2 (Pharmacokinetic properties) of the Summary of Product Characteristics following the conclusions of the assessment report on the evaluation of multiple dose pharmacokinetics of lopinavir/ ritonavir in HIV- infected subjects with mild to moderate hepatic insufficiency.	II/22	II	29.07.04	09.09.04